Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Short Interest Update

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) saw a large decline in short interest in the month of June. As of June 30th, there was short interest totaling 37,772 shares, a decline of 48.4% from the June 15th total of 73,164 shares. Approximately 2.2% of the company’s shares are short sold. Based on an average daily trading volume, of 299,767 shares, the days-to-cover ratio is presently 0.1 days.

Wall Street Analyst Weigh In

Separately, Wall Street Zen cut shares of Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Trading Down 3.6%

Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.09 during trading hours on Wednesday, reaching $2.46. 953,490 shares of the company’s stock were exchanged, compared to its average volume of 308,918. The firm has a market cap of $4.31 million and a PE ratio of -1.21. The business’s 50 day moving average is $8.96. Lakewood-Amedex Biotherapeutics has a fifty-two week low of $2.10 and a fifty-two week high of $98.20.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.